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INTRODUCTION
Transitional cell carcinoma (TCC) of the urinary bladder
can present as a non-muscle invasive or as a muscle-invasive
lesion. The majority of patients (approximately 75%) present
with non-muscle invasive tumors, which are limited to the
mucosa (Ta) or the lamina propria (T1) (1). Carcinoma in situ
(Cis) can also be considered non-muscle invasive. However,
Cis tends to behave more aggressively and is often found in
association with high-grade non-muscle invasive tumors.
Prognostic factors in patients with non-muscle invasive blad-
der cancer have been the subject of numerous publications
for many years (2-18). Depending on a patient’s characteris-
tics, the probability of recurrence after transurethral resection
(TUR) at one year ranges from about 15% to 70% (2), and
the probability of progression at five years ranges from about
7% to 40% (6).
Non-muscle invasive tumors may be managed with TUR
with or without intravesical therapy. However, not all non-
muscle invasive bladder cancer patients have the same risk
for disease recurrence and progression, and the absence of risk
stratification between aggressive and indolent tumors con-
tributes to potentially excessive frequent surveillance or unnec-
essary intravesical therapy. Several studies have suggested risk
tables for the recurrence and progression of non-muscle inva-
sive bladder cancer (5, 7, 9, 10), but they cannot calculate the
probability of a certain event, such as the probability of recur-
rence within five years.
The purpose of this study was to develop and validate prog-
nostic nomograms for disease recurrence in patients with Ta,
T1 transitional cell carcinomas of the bladder. These nono-
grams will facilitate patient counseling, choosing the most
appropriate adjuvant treatment after TUR, and determining
the frequency of follow-up in individual patients.
MATERIALS AND METHODS
Thirty-eight training hospitals participated in this retro-
spective multicenter study. Between January 1998 and Decem-
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Nomograms for Prediction of Disease Recurrence in Patients with
Primary Ta, T1 Transitional Cell Carcinoma of the Bladder
We developed nomograms to predict disease recurrence in patients with Ta, T1
transitional cell carcinoma of the bladder. Thirty-eight training hospitals participated
in this retrospective multicenter study. Between 1998 and 2002, a total of 1,587
patients with newly diagnosed non-muscle invasive bladder cancer were enrolled in
this study. Patients with prior histories of bladder cancer, non-transitional cell carci-
noma, or a follow-up duration of less than 12 months were excluded. With univari-
ate and multivariate logistic regression analyses, we constructed nomograms to
predict disease recurrence, and internal validation was performed using statistical
techniques. Three-year and five-year recurrence-free rates were 64.3% and 55.3%,
respectively. Multivariate analysis revealed that age (hazard ratio [HR]=1.437, p<
0.001), tumor size (HR=1.328, p=0.001), multiplicity (HR=1.505, p<0.001), tumor
grade (HR=1.347, p=0.007), concomitant carcinoma in situ (HR=1.611, p=0.007),
and intravesical therapy (HR=0.681, p<0.001) were independent predictors for dis-
ease recurrence. Based on these prognostic factors, nomograms for the predic-
tion of disease recurrence were developed. These nomograms can be used to
predict the probability of disease recurrence in patients with newly diagnosed Ta,
T1 transitional cell carcinoma of the bladder. They may be useful for patient coun-
seling, clinical trial design, and patient follow-up planning.
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ber 2002, 3,060 patients with newly diagnosed, non-mus-
cle invasive bladder cancer were evaluated. They were treat-
ed with transurethral resection (TUR) and diagnosed with Ta
or T1 TCC of the bladder based on the 2002 American Joint
Committee on Cancer (AJCC) TNM staging system (19).
Patients with prior histories of bladder cancer, non-TCC his-
tology, primary Cis, or a follow-up duration of less than 12
months were excluded. This cohort study was also limited to
tumors whose grades were determined using the 1973 World
Health Organization system. After exclusion, 1,587 patients
were enrolled in this study. The median age was 63 yr (21-
98), and the median follow-up duration was 44 months
(12-97).
The clinical and pathological data (local), including sex,
age, tumor size (<3 cm or ≥3 cm), multiplicity (single or
multiple), T category (Ta or T1), tumor grade, presence of
concomitant Cis or squamous differentiation, and intravesi-
cal therapy were obtained from each hospital and merged. One-
thousand and eighty-two patients were treated with intrav-
esical therapy after TUR, and drugs used for intravesical ther-
apy were as follows: BCG in 827 patients, mitomycin-C in
108 patients, epirubicin in 135 patients, and other drugs in
12 patients. Follow-up data were also obtained, including
pathologically proven recurrence and time to first recurrence,
which was defined as the time period between the date of ini-
tial diagnosis and the date of recurrence. Patients who were
still alive or who had died before a recurrence were censored
at the date of the last available follow-up cystoscopy. Patient
characteristics are summarized in Table 1.
The recurrence-free survival curve was estimated using the
Kaplan-Meier method. We assessed the impact of various
clinical and pathological features on time to first recurrence.
Univariate and multivariate Cox proportional hazard mod-
els and logistic regression models were used. The predictive
accuracy of each univariate and multivariate logistic regres-
sion model was tested using the area under the receiver oper-
ating characteristics (ROC) curve. All univariate and multi-
variate models were internally validated with 500 bootstrap
re-samples as a means of calculating the most unbiased pre-
dictive accuracy. Statistical significance in this study was set
as a p value less than 0.05. All reported p values are two-sided.
All statistical tests were performed using R software (R, ver-
sion 2.4.1, the R Project for Statistical Computing, http://
www.r-project.org). 
RESULTS
Of 1,578 patients, recurrence developed in 605 patients
(38.3%). Three-year and five-year recurrence-free rates were
64.3% and 55.3%, respectively (Fig. 1). On univariate Cox
proportional hazard analysis, age, tumor size, multiplicity,
tumor grade, concomitant Cis, and intravesical therapy had
a significant influence on recurrence-free survival (p<0.05)
(Table 2).
Multivariate analysis revealed that age (hazard ratio [HR]
=1.437, p<0.001), tumor size (HR=1.328, p=0.001), mul-
tiplicity (HR=1.505, p<0.001), tumor grade (HR=1.347,
p=0.007), concomitant Cis (HR=1.611, p=0.007), and
intravesical therapy (HR=0.681, p<0.001) were indepen-
No. of patients (%)
Sex
Male 1,329 (84.2)
Female 249 (15.8)
Age
<65 yr 896 (56.8)
≥65 yr 682 (43.2)
Tumor size
<3 cm 1,130 (71.6)
≤3 cm 448 (28.4)
Multiplicity
Single 874 (55.4)
Multiple 704 (44.6)
T stage
Ta 568 (36.0)
T1 1,010 (64.0)
Tumor grade
Grade I 354 (22.4)
Grade II 918 (58.2)
Grade III 306 (19.4)
Carcinoma in situ
Absence 1,510 (95.7)
Presence 68 (4.3)
Squamous differentiation
Absence 1,499 (95.0)
Presence 79 (5.0)
Intravesical therapy
Not performed 496 (31.4)
Performed 1,082 (68.6)
Total 1,578 (100)
Table 1. Patients characteristics
Fig. 1. Overall recurrence-free probability.
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dent predictors for disease-recurrence (Table 3). Based on this
analysis, nomograms for the prediction of recurrence proba-
bilities at three and five years were constructed (Fig. 2). The
scales of the nomograms reflected the coefficients from the
Cox model rescaled to a user-friendly (100 point) range.
The bootstrapping estimate of the predictive accuracy of the
nomograms suggested that the area under the ROC curve was
approximately 0.599 at three years and 0.604 at five years.
The results of bootstrap re-samples were 0.723 for the three-
year estimation of the nomogram and 0.738 for the five-year
estimation.
DISCUSSION
The prognostic importance of various factors is not always
consistent among various studies, and analyses of prognostic
factors of the bladder TCC related to recurrence are sometimes
difficult to compare (8). This difficulty may be due to differ-
ences in the choice of the variables analyzed, their coding, and,
in multivariate analyses, the correlation among the factors
(10). Another important source of variability stems from dif-
ferences in tumor status, especially between primary or recur-
rent tumors.
This study showed that patient age, tumor size, multiplic-
ity, tumor grade, Cis, and intravesical therapy are significant
predictors for recurrence in patients with Ta, T1 TCC of the
bladder. There was no difference in the time to the first recur-
rence between grade II and grade III tumors in the univariate
analysis, so a dichotomized tumor grade (grade I vs. grade II/
III) was used for the multivariate analysis (Table 2). In addi-
tion, differences among intravesical instillation agents had no
influence on time to first recurrence, and intravesical therapy
was also simply dichotomized (not performed vs. performed)
(Table 2). Of these, multiplicity and intravesical therapy fol-
lowing TUR were the most influential determinants for pre-
diction of recurrence in nomograms (Fig. 2). Tumor grade,
tumor size, and patient age were less strong predictors than
the ones mentioned previously. Concomitant Cis was a rela-
tively weak variable, especially in nomograms for five years
(Fig. 2).
In addition, in this study, the study cohort was limited to
tumors that were newly diagnosed between 1998 and 2002.
Nevertheless, tumor grade, T stage, concomitant Cis, tumor
size, intravesical therapy, tumor status (primary vs. recurrent),
and recurrence rate among other factors were generally iden-
tified as independent prognostic factors for disease recurrence
(2-18). In some studies, age, tumor location, and sex have also
been regarded as independent risk factors (15, 17, 18).
Notably, our nomograms showed that age is a strong deter-
minant for prediction of recurrence. Younger patients appear
to have a more favorable prognosis because they present more
frequently with non-muscle invasive, low-grade tumors. How-
ever, studies have shown that the risk for disease progression
is the same, grade-for-grade, in younger patients as in older
ones (20, 21). In contrast, our results suggest that age has a
prognostic impact independent from other factors. These obser-
vations are consistent with the work by Shariat et al. (22). We
cannot explain why the age factor plays an important role in
disease recurrence. Differences in genetic and molecular aber-
rations in bladder tumors and accumulation of these aberra-
tions in older patients may relate to age. Further investiga-
tion is needed to confirm these hypotheses.
The nomograms in Fig. 2 may be useful for patient counsel-
ing because they predict the probability that the patient will
encounter recurrent bladder cancer within the next three to
five years. They are also effective tools for selecting patients
for experimental adjuvant therapy because they are likely to
be more prognostically accurate than the typical risk strati-
fication approaches that form patient groups by placing cut-
offs on variables. In the context of a randomized clinical trial,
the nomograms may be useful for detecting baseline risk
imbalances between treatment arms. This procedure could
be accomplished by computing predicted probabilities for
each patient, which would simultaneously consider all prog-
nostic variables, and by comparing the predictions across treat-
Hazard 95% Confi-
p value
ratio dence interval
Sex Male vs. female 1.024 0.822-1.277 0.829
Age <65 yr vs. ≥65 yr 1.509 1.286-1.770 <0.001
Tumor size <3 cm vs. ≥3 cm 1.400 1.183-1.657 <0.001
Multiplicity Single vs. multiple 1.549 1.321-1.818 <0.001
T stage Ta vs. T1 1.033 0.874-1.221 0.700
Tumor grade Grade I vs. Grade II 1.495 1.206-1.854 <0.001
Grade I vs. Grade III 1.386 1.065-1.803 0.015
Grade II vs. Grade III 1.079 0.876-1.328 0.474
Carcinoma Absence vs. 1.460 1.038-2.054 0.030
in situ presence
Squamous Absence vs. 0.880 0.606-1.278 0.503
differentiation presence
Intravesical Not performed vs. 0.839 0.710-0.992 0.039
therapy performed
Table 2. Univariate Cox proportional hazard model for time to first
recurrence
Hazard 95% Confi-
p value
ratio dence interval
Age <65 yr vs. ≥65 yr 1.437 1.221-1.691 <0.001
Tumor size <3 cm vs. ≥3 cm 1.328 1.120-1.575 0.001
Multiplicity Single vs. multiple 1.505 1.274-1.777 <0.001
Tumor grade Grade I vs. Grade II/III 1.347 1.087-1.670 0.007
Carcinoma Absence vs. presence 1.611 1.139-2.278 0.007
in situ
Intravesical Not performed vs. 0.681 0.572-0.810 <0.001
therapy performed
Table 3. Multivariate Cox proportional hazard model for time to
first recurrence
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Points
Age (yr)
Multiplicity
Tumor size
Tumor grade
Carcinoma in situ
Intravesical therapy
Total points
Linear predictor
3-yr recurrence probabilities
0 10 20 30 40 50 60 70 80 90 100
0 50 100 150 200 250 300 350 400 450
-1.8 -1.4 -1 -0.8 -0.4 0 0.2 0.4 0.6
0.2 0.3 0.4 0.5 0.6
<65
<3 cm
Single
Grade I
No
No
Yes
Yes
Grade II/III
Multiple
≥65
≥3 cm
A
Points
Age (yr)
Multiplicity
Tumor size
Tumor grade
Carcinoma in situ
Intravesical therapy
Total points
Linear predictor
5-yr recurrence probabilities
0 10 20 30 40 50 60 70 80 90 100
0 50 100 150 200 250 300 350 400 450
-1.6 -1.2 -1 -0.8 -0.4 0 0.2 0.4 0.6 0.8
0.2 0.3 0.4 0.5 0.6
<65
<3 cm
Single
Grade I
No
No
Yes
Yes
Grade II/III
Multiple
≥65
≥3 cm
B
Fig. 2. Nomograms to predict first recurrence at three years (A) and at five years (B).
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ment arms. In our study, we suggested two nomograms that
were very similar, but there were some differences in the
weight of risk score. The nomogram for three years would
be more suitable for short-term studies, and the five-year no-
mogram may be helpful for long-term studies. Additionally,
nomograms may aid in determining the scheduling of follow-
up visits, as patients at lower risk for relapse or a second prima-
ry tumor may require less stringent follow-up evaluations (23).
The nomogram in Fig. 2 has several weaknesses. An impor-
tant limitation to consider is that the nomogram is not entire-
ly accurate. The prediction for the area under the ROC curve
was approximately 0.599 for the three-year nomogram and
was 0.604 for the five-year nomogram. Despite being imper-
fect, the nomogram may provide the most accurate predic-
tions currently available. Another limitation is that the nomo-
gram predicts disease recurrence only within a maximum
period of five years. The nomogram is additionally limited
because it relies on postoperative variables, making it an
inadequate preoperative patient counseling tool. It is impor-
tant to remember that adjuvant therapy performed in this
data set was a mixture of various intravesical therapies, and
the decision as to which instillation drug should be chosen
was left to the physicians. Finally, experiencing a beneficial
effect on intravesical therapy in this study does not mean
that adjuvant intravescial therapy has to be performed in all
cases of non-muscle invasive bladder tumors.
The nomograms for non-muscle invasive bladder cancer in
which a point system was used are very rare. To our knowledge,
only Shariat et al. (22) have reported that nomograms for non-
muscle invasive bladder cancer can predict recurrence and
progression, which included nuclear matrix protein 22 and
cytology, as well as conventional predictors. We tested only
conventional variables without ancillary markers, i.e., nucle-
ar matrix protein 22. For this reason, the nomograms in our
study may be more feasible in common clinical settings.
In conclusion, current nomograms can be used to predict
the probability of disease recurrence in patients with newly
diagnosed Ta, T1 transitional cell carcinoma of the bladder.
They may be useful for patient counseling, clinical trial design,
and patient follow-up planning.
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